Zhejiang Kanglaite Pharmaceutical Co., Ltd. is a ?ate Key High-tech Enterprise entitled by China Ministry of Science & Technology. Covering an area of 7 hectares and a total floor space of 28,000 sq. m, the LVP production line and auxiliary equipment were totally introduced from Europe and USA. International GMP standard is strictly followed in production. There are over 500 staff of whom 60% are with university diploma. And 32 regional offices in China offer a strong momentum in expanding domestic market. 



As "State Basic Drug" and "State Medical Insurance Drug", Kanglaite Injection (KLT) is a novel dual-function, broad spectrum and molecular targeting anticancer agent with its active substance extracted from a medicinal herb "semen coicis" by state of the art technology. KLT has remarkable function in inhibiting and killing various cancer cells while strengthening immune function. In addition it has significant effectiveness in controlling cancerous pain, resisting cachexia, preventing cancer metastasis, improving Kanovsky score and prolonging patient survival period. 



Experience from basic research and long term clinical application has shown that KLT presents good effect in treatment of cancers mainly at sites of lung, liver, stomach, breast, prostate and malignant lymphoma, etc. It has brought great benefits to over 550,000 patients after being launched in China. In 2005 the annual turnover reached US$37 million. 



KLT has full intellectual property. Its chemical component, process technology and application have obtained patent certificates from over 10 countries including China, USA, EC, Russia, Japan, Korea and Indonesia. In 2001 FDA approved KLT to start clinical study in USA and the Russian Ministry of Health issued registration certificate in December 2003. 



Currenly the manufactirer is seeking agent and distributor in Latin American region for KLT with preferential policies.



Serious and experienced companies preferably in oncological line are welcome to directly contact us. Thanks.